Psilocybin at the FDA Gate: Phase 3 Signal Meets Unresolved Infrastructure and Durability Gaps

FDA Hearing on Psychedelic Therapies Signals Growing Support

The FDA is holding a public hearing on September 14, 2026, to discuss psychedelic drug development, amidst widespread public and regulatory support. This follows recent FDA guidance and leadership appointments favorable to the emerging drug class. Analysts anticipate potential launches of psychedelic treatments, such as Compass Pathways' psilocybin-based COMP360 for depression, which is expected to receive FDA approval by late 2026 or early 2027 based on positive Phase 3 data. The hearing will address critical aspects like provider training, patient safety, access issues, and data standardization for psychedelic medications.

• The upcoming FDA hearing is underpinned by significant support from a broad ecosystem of stakeholders, including patients, doctors, interventional psychiatry centers, the FDA, HHS, the White House, and Veterans Affairs. This momentum is further bolstered by the Trump administration's executive order in April, directing federal agencies to advance psychedelic drug development and regulation, signaling a coordinated governmental effort beyond mere rhetoric.
• Compass Pathways' COMP360, a psilocybin-based candidate for depression, is a frontrunner, with Jefferies analysts projecting 75-85% confidence in FDA approval by late 2026 or early 2027, following durable Phase 3 data. Definium Therapeutics' oral LSD candidate, DT120, is also showing positive late-stage data for generalized anxiety disorder and major depressive disorder, indicating a robust pipeline in the psychedelic space.
• The FDA has demonstrated a proactive and receptive approach to psychedelic therapies, evidenced by updated guidance for developers in July and the recent appointments of Michael Davis and Karim Mikhail as directors of CDER and CBER, respectively. Davis, with prior experience in psychedelic development, co-authored an article in The New England Journal of Medicine outlining the FDA’s new framework, underscoring the agency's commitment to addressing the mental health crisis through these compounds.
• The psychedelic market is gaining commercial traction, building on the success of Johnson & Johnson’s esketamine-based Spravato, which achieved $584 million in Q2 sales. This growing interest is reflected in recent significant acquisitions by major pharmaceutical companies, including Eli Lilly's up to $3.8 billion purchase of AtaiBeckley, AbbVie's $1.2 billion Gilgamesh Pharmaceuticals buy, and Otsuka's acquisition of Transcend Therapeutics for over $1 billion.

Addressing Unmet Needs in Depression: Why Psychedelics?

Despite decades of pharmacological development, current treatment approaches for major depressive disorder (MDD) remain constrained by a set of persistent clinical and mechanistic limitations that continue to drive unmet need across patient populations.

• Trial-and-error prescribing: Treatment of MDD often entails a trial-and-error process of finding a suitable antidepressant and its appropriate dose, with no validated biomarkers yet confirmed to reliably predict response to specific agents, including tricyclic antidepressants (TCAs), SSRIs, or SNRIs.

• Delayed onset of action: New-generation monoaminergic antidepressants, such as selective-serotonin and dual-acting serotonin/norepinephrine reuptake inhibitors, are associated with a long latency of onset of antidepressant action, delaying meaningful symptom relief for patients.

• Tolerability and adherence barriers: SSRIs and SNRIs can cause nausea, headache, sleep disturbances, dry mouth, weight gain, and sexual dysfunction. Sexual side effects in particular may affect compliance and adherence to treatment, with increased drop-out rates noted in specific clinical populations such as youths.

• Low response rates and high relapse burden: Current monoaminergic treatments are associated with a low rate of response and a high rate of relapse/recurrence, leaving a substantial proportion of patients inadequately managed on standard regimens.

• Persistence of cognitive and anhedonic symptoms: The classical monoamine hypothesis does not fully account for variability in treatment response, delayed therapeutic onset, or the persistence of cognitive and anhedonic symptoms, pointing to mechanistic gaps in existing pharmacological strategies.

• Limitations of rapid-acting alternatives: While intranasal esketamine has demonstrated rapid symptom relief in treatment-resistant depression (TRD) — producing a significant improvement in MADRS scores within 24 hours (mean difference -3.44; 95% CI -5.51 to -1.38) — it is associated with a higher incidence of adverse events, including elevated blood pressure (RR 3.10; 95% CI 2.24–4.29) and dissociation (RR 5.90; 95% CI 4.32–8.05). Long-term safety, durability of response, and real-world tolerability remain insufficiently explored.

• Biological heterogeneity not captured by current diagnostics: MDD exhibits substantial biological heterogeneity that is not adequately captured by current symptom-based diagnostic systems, complicating the identification of mechanism-informed treatment strategies and the development of predictive biomarkers.

COMP360 and DT120: Psychedelic Candidates Nearing Approval

Several recent randomized controlled trials have examined pharmacological interventions for depression, spanning bipolar depression, major depressive disorder, and treatment-resistant late-life depression. The studies below capture a range of interventions with distinct efficacy and safety profiles.

Big Pharma's Growing Interest in the Psychedelic Treatment Landscape

The depression treatment landscape has undergone meaningful diversification over the past five years, with clinical trial data supporting novel pharmacological, neuromodulatory, and psychedelic-assisted approaches. Among pharmacological advances, intranasal esketamine — a modulator of NMDA receptors involved in glutamatergic neurotransmission — has demonstrated sustained efficacy in treatment-resistant depression (TRD) across long-term extension data from the SUSTAIN-3 study. In that study, 1,148 participants were enrolled, with a mean exposure of 42.9 months and total exposure reaching 3,777 cumulative patient-years. Mean Montgomery-Åsberg Depression Rating Scale (MADRS) total scores decreased during induction (mean [SD] change: -12.8 [9.73]) and this reduction persisted during optimization/maintenance (+0.2 [9.93]), with 48.5% and 49.6% of participants in remission at week 112 and optimization/maintenance endpoint, respectively. No new safety signals were identified during long-term treatment. Separately, allopregnanolone agonists — brexanolone and zuranolone — have emerged as a novel mechanistic class, with brexanolone demonstrating significantly reduced Hamilton Depression Rating Scale (HAM-D) scores versus placebo in postpartum depression (PPD), and zuranolone showing significant HAM-D reductions in major depressive disorder (MDD) at days 15 and 28 compared to placebo.

Psilocybin-assisted psychotherapy has attracted growing clinical scrutiny as a potential alternative to standard antidepressants. A phase 2, double-blind, randomised, controlled trial comparing two 25 mg doses of psilocybin with psychological support against a 6-week course of escitalopram (10 mg for three weeks, then 20 mg for three weeks) in patients with moderate-to-severe MDD found that both treatments yielded sustained improvements in depressive symptom severity at 6-month follow-up, with a mean between-condition difference in QIDS-SR-16 scores of 1.51 (95% CI: -1.35, 4.38; p = 0.311). Psilocybin therapy demonstrated greater mean between-condition differences in functioning (WSAS: -7.46; 95% CI: -12.4, -2.47; p < 0.001), psychological connectedness (WCS: 11.02; 95% CI: 1.25, 20.83; p = 0.033), and meaning in life (MLQ: 4.86; 95% CI: 0.67, 9.05; p = 0.021) compared to escitalopram treatment. A subsequent Bayesian reanalysis of a psilocybin versus escitalopram trial found extremely strong evidence for psilocybin's non-inferiority versus escitalopram across outcome measures, and strong to extremely strong evidence for psilocybin superiority on BDI-1A and HAMD-17, though not to a clinically meaningful extent on all scales.

Neuromodulatory strategies have also advanced considerably. Connectivity-guided intermittent theta burst stimulation (cgiTBS), personalised using resting-state functional MRI to target effective connectivity from the right anterior insula to the left dorsolateral prefrontal cortex, was evaluated against structural MRI-neuronavigated repetitive transcranial magnetic stimulation (rTMS) in a five-centre, parallel, double-blind, randomised controlled trial. Persistent decreases in depressive symptoms were observed over 26 weeks, with no significant differences between arms on the primary outcome GRID Hamilton Depression Rating Scale 17-item score (intention-to-treat adjusted mean: -0.31, 95% CI -1.87, 1.24, P = 0.689), indicating that both approaches were equally effective. Additionally, a case report of accelerated continuous theta burst stimulation (a-cTBS) targeting the right dorsolateral prefrontal cortex — delivering 18,000 pulses each day for 5 consecutive days — in a patient who had not responded to pharmacotherapy, intermittent theta burst stimulation, or electroconvulsive therapy, reported a Montgomery Depression Rating Scale score decrease from 32 to 9, a Hamilton Anxiety Rating Scale score drop from 20 to 6, and resolution of suicidal ideation, suggesting a-cTBS as a viable alternative for patients with TRD who do not benefit from existing treatment modalities.

Psychedelics at the Precipice: Navigating a New Therapeutic Frontier

The upcoming FDA public hearing on psychedelic drug development is more than a procedural event; it signifies a profound shift in how regulatory bodies are approaching mental health innovation. With widespread public and regulatory support, and recent favorable guidance, the stage is being set for a new class of treatments that could redefine care for millions.

At the forefront of this emerging field is Compass Pathways' psilocybin-based COMP360, which is showing significant promise for major depressive disorder (MDD) and treatment-resistant depression (TRD). Clinical trials and meta-analyses indicate that a single dose of psilocybin, administered with psychological support, can lead to clinically significant and sustained reductions in depressive symptoms and functional disability. These rapid antidepressant effects offer a compelling alternative to existing treatments, which often take weeks to show benefit. Beyond depression, there's a growing rationale for exploring psychedelic-assisted psychotherapy (PAP) in other areas, such as caregiver distress, suggesting a broader therapeutic potential.

However, realizing this potential requires careful navigation. The unique nature of psychedelic experiences introduces methodological challenges in clinical trials, particularly around blinding and managing patient expectations, which researchers are actively working to address. While serious adverse events have not been consistently reported, a higher incidence of general adverse events like headache and nausea is noted, and the long-term safety profile, especially concerning suicide-related outcomes, demands rigorous, ongoing evaluation.

Strategically, the successful integration of these therapies will hinge on establishing a robust care delivery infrastructure. This includes comprehensive provider training, standardized psychological support protocols, and controlled administration environments. These requirements, while crucial for patient safety and efficacy, also present significant hurdles for widespread patient access and commercial scalability. As the FDA moves towards potential approvals, the industry must proactively address these complexities to ensure that this promising new frontier in mental health care can truly reach those who need it most.